Operating Company Healthcare

Curium

Paris, France

Curium is a global nuclear medicine company that develops, manufactures and distributes radiopharmaceuticals, and provides nuclear medicine diagnostics and therapeutics.

Focus Areas
Radiopharmaceutical manufacturing, Nuclear medicine supplies, PET/SPECT products

Tracked deals

3

3 tracked deals across 2020-2026.

Recent pace

2

2 tracked deals announced in the last 12 months.

Deal mix

Buyout

3 buyout

Curium Acquisition Volume by Year

Last 2 years

Acquisition volume by year Annual acquisition counts for the last 2 years for Curium. 1 2020 ~3 est. 2 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Curium Acquires Abscint SA (ABS-011) to Expand HER2 PET Radiodiagnostic Pipeline
    August 10, 2026
    Buyer
    Curium
    Target
    Abscint SA
    Industry
    Healthcare Services
    Location
    Belgium
    Type
    Buyout

    Curium, a global radiopharmaceutical company, completed its acquisition of Abscint SA, a Belgian clinical-stage molecular imaging company. The deal gives Curium the global rights to develop, manufacture, and commercialize ABS-011, a Phase 2b gallium-68-labeled HER2-targeting PET radiodiagnostic tracer currently evaluated in the HERMIA trial in Belgium.

  • Curium US Holdings to Acquire Lantheus Holdings in Up to $8.0B Deal
    August 3, 2026
    Buyer
    Curium US Holdings LLC, Curium, CapVest Partners LLP
    Target
    Lantheus Holdings, Inc.
    Industry
    Healthcare Services
    Location
    Massachusetts, United States
    Type
    Buyout

    Curium US Holdings LLC has entered into a definitive agreement to acquire all outstanding shares of Lantheus Holdings, Inc. for $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights (CVRs) potentially paying up to an additional $12.00 per share tied to commercial milestones through 2030. The transaction is valued at up to approximately $8.0 billion and is expected to close in the first half of 2027, subject to customary approvals and regulatory clearances.

  • Curium Acquires Zevacor Molecular
    March 3, 2020
    Buyer
    Curium
    Target
    Zevacor Molecular
    Industry
    Pharmaceuticals
    Location
    Indiana, United States
    Type
    Buyout

    Curium has acquired Zevacor Molecular, a producer of Strontium-82 used to make Rubidium-82 generators for cardiac PET imaging. The acquisition expands Curium's PET product capabilities and brings Zevacor's manufacturing infrastructure and employees into the Curium organization.

Related Acquisition Pages

Healthcare Services Buyers & Acquisitions 2 tracked deals by Curium. Pharmaceuticals Buyers & Acquisitions 1 tracked deal by Curium. Acquisitions in Indiana 1 tracked deal by Curium. Acquisitions in Massachusetts 1 tracked deal by Curium.

Related articles

Selling a company? Get in front of buyers like Curium

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →